NUVB vs. NRIX, BCYC, ANAB, MLYS, DNTH, WVE, PAHC, CVAC, SVRA, and SLN
Should you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include Nurix Therapeutics (NRIX), Bicycle Therapeutics (BCYC), AnaptysBio (ANAB), Mineralys Therapeutics (MLYS), Dianthus Therapeutics (DNTH), Wave Life Sciences (WVE), Phibro Animal Health (PAHC), CureVac (CVAC), Savara (SVRA), and Silence Therapeutics (SLN). These companies are all part of the "pharmaceutical preparations" industry.
Nuvation Bio (NYSE:NUVB) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk.
Nuvation Bio has higher earnings, but lower revenue than Nurix Therapeutics. Nuvation Bio is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.
Nurix Therapeutics received 19 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 71.43% of users gave Nuvation Bio an outperform vote while only 71.01% of users gave Nurix Therapeutics an outperform vote.
Nuvation Bio has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500.
Nuvation Bio presently has a consensus price target of $6.60, indicating a potential upside of 99.70%. Nurix Therapeutics has a consensus price target of $21.14, indicating a potential upside of 41.42%. Given Nuvation Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Nuvation Bio is more favorable than Nurix Therapeutics.
Nuvation Bio has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -178.93%. Nuvation Bio's return on equity of -12.21% beat Nurix Therapeutics' return on equity.
In the previous week, Nurix Therapeutics had 8 more articles in the media than Nuvation Bio. MarketBeat recorded 10 mentions for Nurix Therapeutics and 2 mentions for Nuvation Bio. Nurix Therapeutics' average media sentiment score of 0.37 beat Nuvation Bio's score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the news media.
61.7% of Nuvation Bio shares are owned by institutional investors. 36.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 9.8% of Nurix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Nuvation Bio beats Nurix Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Nuvation Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvation Bio Competitors List
Related Companies and Tools
